Atherton F R, Hall M J, Hassall C H, Holmes S W, Lambert R W, Lloyd W J, Nisbet L J, Ringrose P S, Westmacott D
Antimicrob Agents Chemother. 1981 Oct;20(4):470-6. doi: 10.1128/AAC.20.4.470.
The phosphonopeptide alafosfalin (L-alanyl-L-1-aminoethylphosphonic acid) exhibited synergy in vitro and in animal studies against a range of bacterial genera when combined with cephalexin. Alafosfalin also showed synergy with mecillinam and, to a much lesser extent, with ampicillin. Synergy with cephalexin was more pronounced when the bacteria were relatively insensitive to the beta-lactam component. The action of this combination involved both an inhibitory and a bacteriolytic mechanism which was abolished by concurrent treatment with the aminopeptidase inhibitor, bestatin. Regrowth of subpopulation resistant to either component was markedly reduced by the combination. The potential of alafosfalin combined with cephalexin for use in therapy is discussed.
膦肽阿拉磷(L-丙氨酰-L-1-氨基乙基膦酸)在体外和动物研究中显示,与头孢氨苄联合使用时,对一系列细菌属具有协同作用。阿拉磷与美西林也显示出协同作用,与氨苄西林的协同作用程度则小得多。当细菌对β-内酰胺成分相对不敏感时,与头孢氨苄的协同作用更为明显。这种联合用药的作用涉及抑制和溶菌机制,而氨基肽酶抑制剂贝他汀的同时治疗可消除该机制。联合用药显著减少了对任何一种成分耐药的亚群的再生长。文中讨论了阿拉磷与头孢氨苄联合用于治疗的潜力。